Sign in

SNES on Nasdaq

SenesTech, Inc.

SenesTech, Inc. is an American agricultural chemicals company based in Phoenix.1 Its shares trade on Nasdaq under the symbol SNES.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Cibus, Inc., Evogene Ltd or Bioceres Crop Solutions Corp., or pick any stock.

  • TickerSNES on Nasdaq1
  • IndustryAgricultural Chemicals1
  • HeadquartersPhoenix, Arizona1
  • Incorporated inDE2
  • Business address777 W. Pinnacle Peak Road, Suite B104, Phoenix, Az 850272
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

The abbreviations or acronym defined below are used throughout this Annual Report on Form 10-K:3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

62.5%Gross margin4
-292.9%Operating margin4
-287.4%Net margin4
19.6%Revenue growth, 20254
-66.7%Return on equity4
-$5.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue33¢$833.0K
  • Research and development67¢$1.7M

Out of $2.2M in revenue.4 The company lost money this year.

Financial statements

Revenue567894$2.2M in 2025+1453% since 2019
0$1.0M$2.0M$3.0M2019: $143.0K$143.0K20192020: $282.0K$282.0K2020+97%2021: $600.0K$600.0K2021+113%2022: $1.0M$1.0M2022+70%2023: $1.2M$1.2M2023+17%2024: $1.9M$1.9M2024+56%2025: $2.2M$2.2M2025+20%
Gross profit567894$1.4M in 2025+3205% since 2019
0$500.0K$1.0M$1.5M2019: $42.0K$42.0K20192020: $1.0K$1.0K2020−98%2021: $244.0K$244.0K2021+24300%2022: $464.0K$464.0K2022+90%2023: $539.0K$539.0K2023+16%2024: $1.0M$1.0M2024+86%2025: $1.4M$1.4M2025+38%
Operating income567894-$6.5M in 2025−37% since 2019
-$15.0M-$10.0M-$5.0M02019: -$10.3M-$10.3M20192020: -$7.9M-$7.9M2020−23%2021: -$8.9M-$8.9M2021+13%2022: -$9.7M-$9.7M2022+8%2023: -$7.7M-$7.7M2023−20%2024: -$6.2M-$6.2M2024−19%2025: -$6.5M-$6.5M2025+4%
Net income567894-$6.4M in 2025−36% since 2019
-$15.0M-$10.0M-$5.0M02019: -$10.0M-$10.0M20192020: -$8.4M-$8.4M2020−16%2021: -$8.3M-$8.3M2021−1%2022: -$9.7M-$9.7M2022+17%2023: -$7.7M-$7.7M2023−20%2024: -$6.2M-$6.2M2024−20%2025: -$6.4M-$6.4M2025+3%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenues$2.2M$1.9M
Cost of sales$833.0K$853.0K
Gross profit$1.4M$1.0M
Research and development$1.7M$1.7M
Selling, general and administrative$6.2M$5.5M
Total operating expenses$7.9M$7.3M
Loss from operations-$6.5M-$6.2M
Interest income$144.0K$56.0K
Interest expense-$22.0K-$22.0K
Miscellaneous income$0$31.0K
Other income, net$122.0K$65.0K
Net loss-$6.4M-$6.2M
Comprehensive loss-$6.4M-$6.2M
Weighted average shares outstanding - basic (in shares)3.3M shares698.0K shares
Weighted average shares outstanding - diluted (in shares)3.3M shares698.0K shares
Loss per share - basic (in dollars per share)-$1.95-$8.86
Loss per share - diluted (in dollars per share)-$1.95-$8.86

Compare SenesTech, Inc. with another company

Corporate structure

SenesTech, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SenesTech, Inc.

  • GLENBROOK CAPITAL MANAGEMENT Filed SCHEDULE 13D on SenesTech, Inc., latest Jul 23, 2026 (4 filings since Nov 24, 2025)
  • PFS CAP MGT CO Filed SCHEDULE 13G/A on SenesTech, Inc., latest Aug 12, 2025 (4 filings since Nov 12, 2024)
  • Lind Global Fund II LP Filed SCHEDULE 13G/A on SenesTech, Inc., latest May 15, 2025 (6 filings since Apr 17, 2023)
  • Lind Global Macro Fund LP Filed SC 13G/A on SenesTech, Inc., latest Nov 14, 2024 (2 filings since Feb 11, 2022)
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on SenesTech, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G on SenesTech, Inc., latest Apr 19, 2023 (2 filings since Feb 11, 2022)
  • Sandpiper Capital Filed SC 13G/A on SenesTech, Inc., latest Jan 5, 2023 (2 filings since Jan 31, 2022)
  • SenesTech, Inc. Phoenix, Arizona

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SenesTech, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$1.2M4 Dec 31, 2025$2.2M4 Dec 31, 2024−47.8%
Property and equipment, net$410.0K4 Dec 31, 2025$407.0K4 Dec 31, 2024+0.7%
Operating-lease assets (leased space)$2.3M4 Dec 31, 2025$04 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.6M4 Dec 31, 2025$1.3M4 Dec 31, 2024+479.6%
Marketable securities, current$994.0K4 Dec 31, 2025$04 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Patents, net$09 Dec 31, 2024$14.0K9 Dec 31, 2023−100.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$994.0K4 Dec 31, 2025$794.0K4 Dec 31, 2024+25.2%
Raw materials$726.0K4 Dec 31, 2025$719.0K4 Dec 31, 2024+1.0%
Work in process$04 Dec 31, 2025$1.0K4 Dec 31, 2024−100.0%
Finished goods$268.0K4 Dec 31, 2025$74.0K4 Dec 31, 2024+262.2%

Properties, in its own words

As of December 31, 2025, we lease and occupy approximately 17,000 square feet of space in Surprise, Arizona for our corporate, manufacturing and research operations pursuant to a lease that expires in May 2035.

We believe that our existing facilities are adequate and meet our current needs for business, manufacturing and research.

Item 2 of the 10-K filed Mar 13, 2026.3

Leadership

Who has led SenesTech, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Loretta Powers Mayer2016–2019
  2. Thomas C. Chesterman2017
  3. Kenneth S. Siegel2019–2022
  4. Joel Lee Fruendt2022–2024
  5. Michael Edell2026–now

Chief financial officer

  1. Thomas C. Chesterman2016–now

Chief operating officer

  1. Andrew Altman2017–2018
20202025
Board members and other officers (24)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Revenue OfficerNicole L. Williams named Apr 26, 202338
  • DirectorJake S. Leach named Apr 26, 2023 to Aug 12, 202539
  • DirectorJamie L. Bechtel, JD, Ph.D. named Apr 26, 2023 to Aug 12, 202539

Timeline

  1. Oct 15, 20268-K Results of operations40
  2. Aug 5, 20268-K Results of operations41
  3. Aug 3, 20268-K Results of operations42
  4. Jun 10, 20268-K Shareholder vote43
  5. May 18, 2026New chief executive Michael Edell becomes CEO12
  6. May 12, 20268-K Results of operations44
  7. May 7, 20268-K Executive or director change45
  8. Mar 12, 20268-K Results of operations46
  9. Jan 28, 20268-K Executive or director change47
  10. Jan 28, 20268-K Executive or director change48
  11. Nov 14, 20258-K Executive or director change49
  12. Nov 10, 20258-K Results of operations50
  13. Oct 21, 20258-K Executive or director change51
  14. Nov 23, 2022New chief executive Joel Lee Fruendt becomes CEO13
  15. Jun 19, 2019New chief executive Kenneth S. Siegel becomes CEO14
  16. Apr 24, 2017New chief executive Thomas C. Chesterman becomes CEO15
  17. Dec 7, 2016New chief executive Loretta Powers Mayer becomes CEO16

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.28) a share, on Nov 10, 2025.52

When it reported results

  1. Oct 15, 2026Reported quarterly or annual results40
  2. Aug 5, 2026Reported quarterly or annual results41
  3. Aug 3, 2026Reported quarterly or annual results42
  4. May 12, 2026Reported quarterly or annual results44
  5. Mar 12, 2026Reported quarterly or annual results46
  6. Nov 10, 2025Reported quarterly or annual results50
  7. Aug 7, 2025Reported quarterly or annual results53
  8. May 8, 2025Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

259 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 63 major events, 64 insider forms, 22 large holders, 6 private raises, 83 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 29, 20264 EDGAR
  3. Sep 15, 20264 EDGAR
  4. Sep 10, 20264 EDGAR
  5. Aug 20, 2026S-8 EDGAR
  6. Aug 17, 20264 EDGAR
  7. Aug 10, 20264 EDGAR
  8. Aug 6, 202610-Q EDGAR
  9. Aug 5, 20268-K EDGAR
  10. Aug 3, 20268-K EDGAR
  11. Jul 23, 2026SCHEDULE 13D EDGAR
  12. Jul 22, 20264 EDGAR
  13. Jul 8, 20264 EDGAR
  14. Jul 2, 20264 EDGAR
  15. Jun 29, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 17, 20264 EDGAR
  18. Jun 17, 20264 EDGAR
  19. Jun 17, 20264 EDGAR
  20. Jun 17, 20264 EDGAR

The 259 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

40 open-market trades by officers, directors and large owners since October 2021: 38 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 28, 2026Edell MichaelChief Executive OfficerBuy2,000$0.64$1.3KForm 4
Sep 14, 2026Edell MichaelChief Executive OfficerBuy1,000$0.84$840Form 4
Sep 9, 2026Edell MichaelChief Executive OfficerBuy2,000$0.87$1.7KForm 4
Aug 14, 2026Edell MichaelChief Executive OfficerBuy1,000$1.21$1.2KForm 4
Aug 7, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy6,490$1.30$8.4KForm 4
Aug 6, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy15,000$1.30$19.5KForm 4
Jul 20, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy35,000$1.47$51.5KForm 4
Jul 7, 2026Edell MichaelChief Executive OfficerBuy1,000$1.43$1.4KForm 4
Jun 30, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy35,000$1.51$52.9KForm 4
Jun 29, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy5,172$1.52$7.9KForm 4
Jun 26, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy6,812$1.56$10.6KForm 4
Jun 25, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy9,442$1.53$14.4KForm 4
Jun 24, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy3,990$1.55$6.2KForm 4
Jun 22, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy5,000$1.66$8.3KForm 4
Jun 17, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy3,264$1.61$5.3KForm 4
Jun 8, 2026Edell MichaelChief Executive OfficerBuy1,000$1.55$1.6KForm 4
Jun 8, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy7,000$1.61$11.3KForm 4
Jun 5, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy13,159$1.57$20.7KForm 4
Jun 4, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy8,230$1.65$13.6KForm 4
May 18, 2026GLENBROOK CAPITAL MANAGEMENT10% ownerBuy10,000$1.59$15.9KForm 4

All 40 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Joel L. Fruendt65$357.0K$360.0K62
2025Thomas C. Chesterman66$262.5K$309.7K62
2025Michael Edell63$60.0K$180.6K62
2024President and Chief Executive Officer$344.9K$565.1K62
2024Executive Vice PresidentChief Financial Officer, Treasurer and Secretary$261.5K$373.6K62

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 4, 2025Raised $273,539 in a private offering of securities Form D: 5 investors so far Form D
  2. Jun 30, 2025Raised $182,359 in a private offering of securities Form D: 5 investors so far Form D
  3. Mar 9, 2025Filed a private offering of securities Form D: 5 investors so far Form D
  4. Aug 22, 2024Filed a private offering of securities Form D: 6 investors so far Form D
  5. Aug 21, 2023Filed a private offering of securities Form D: 1 investor so far Form D
  6. Apr 10, 2023Raised $1.5 million in a private offering of equity Form D: 4 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sabby Management, LLC141,756$211.2K1.8%−76,777
Renaissance Technologies LLC82,616$123.1K0.0%−31,384
Citadel Advisors LLC46,671$69.5K0.0%+35,352
Geode Capital Management, LLC44,339$66.1K0.0%−18,767
Vanguard Capital Management LLC34,762$51.8K0.0%−8,103
Vanguard Fiduciary Trust Co26,594$39.6K0.0%−5,100
Essex Investment Management Co LLC26,203$39.0K0.0%−91
Northern Trust Corp17,587$26.2K0.0%New
Diversify Advisory Services, LLC19,119$25.4K0.0%New
Diversify Wealth Management, LLC19,119$25.4K0.0%No change
State Street Corp16,662$24.8K0.0%No change
XTX Topco Ltd10,308$15.4K0.0%−10,753
Morgan Stanley3,400$5.1K0.0%No change
UBS Group AG1,307$1.9K0.0%−19,582
Osaic Holdings, Inc.1,000$1.5K0.0%−4,000
Barclays PLC106$1580.0%New
Caitong International Asset Management Co., Ltd13$190.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How SenesTech, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSenesTech, Inc.1
  • CIK0001680378
  • Employer ID (EIN)20-20798053
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2870 Agricultural Chemicals1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address777 W. Pinnacle Peak Road, Suite B104, Phoenix, AZ 850271
  • Mailing addressPo Box 3627, Flagstaff, AZ 860031
  • Phone(928) 779 - 41431
  • Shares outstanding5,423,542 as of Aug 4, 202611
  • Public float$19.2M as of Jun 30, 20253
  • AuditorM&K CPAS, PLLC, The Woodlands, TX PCAOB ID 2738; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 3, 20161
  • Filings639 in all: 4 (189), 8-K (122), CORRESP (37), 10-Q (29), 3 (25), EFFECT (21), UPLOAD (21), SC 13G/A (17)1
    All 38 form types

    DEFA14A (15), SC 13G (15), DEF 14A (13), S-1/A (13), 424B5 (11), 10-K (10), D (10), S-3 (10), S-1 (9), S-8 (8), 4/A (7), 424B3 (7), PRE 14A (7), SCHEDULE 13G/A (7), 424B4 (6), 10-K/A (5), 10-Q/A (3), 8-K/A (3), FWP (3), POS AM (3), S-3/A (3), DRS (2), 3/A (1), 8-A12B (1), 8-A12G (1), CERTNAS (1), CT ORDER (1), S-8 POS (1), SCHEDULE 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 13, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par valueSNESThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 13, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks SenesTech, Inc. names in Item 1A of its 10-K filed Mar 13, 2026: 30 risks under these headings, as written.3

  • Risks Related to our Business
  • Our success is dependent on the successful commercialization of ContraPest and Evolve.
  • ContraPest, Evolve, and our other product candidates may not achieve adequate market acceptance necessary for commercial success.
  • If we cannot successfully commercialize our products, especially ContraPest and Evolve, we will not become profitable.
  • We will require additional capital to fund our operations. Failure to obtain this necessary capital if needed may force us to delay, limit, or terminate our product development efforts or other operations.
  • If we are unable to establish and maintain an effective sales force and marketing and distribution infrastructures, or enter into and rely upon acceptable third-party relationships, we may be unable to generate sufficient revenues to become profitable.
  • The misuse of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
  • We are currently operating in a period of economic uncertainty, which has been significantly impacted by geopolitical instability, inflation, increases in interest rates, and other disruptions in credit and financial markets.
  • We could be required to collect additional sales, value added or similar taxes or be subject to other tax liabilities that may increase the costs our clients would have to pay for our products and adversely affect our results of operations.
  • Risks Related to Regulatory Matters
  • Regulatory approval processes of the EPA, state and comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may fail.
  • Even following receipt of any regulatory approval for ContraPest, Evolve, and our other product candidates, requiring regulatory approval, we will continue to face extensive regulatory requirements and our products may face future development and regulatory difficulties.
The other 20 risks
  • Even after receiving any regulatory approval or introducing products or product candidates, we will continue to be subject to regulation of our manufacturing processes and advertising practices.
  • Failure to obtain regulatory approval in foreign jurisdictions would prevent our products or product candidates from being marketed in those jurisdictions.
  • Risks Related to our Operations and Supply Chain
  • We depend on key personnel to operate our business. If we are unable to retain, attract and integrate qualified personnel, our ability to develop and successfully grow our business could be harmed.
  • Business or supply chain disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.
  • A variety of risks associated with marketing our products and product candidates internationally could materially adversely affect our business.
  • Risks Related to Our Intellectual Property and Legal Actions
  • If we fail to obtain or protect intellectual property rights, our competitive position could be harmed.
  • Intellectual property rights do not necessarily address all potential threats to any competitive advantage we may have.
  • Our technology may be found to infringe third-party intellectual property rights.
  • We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • We may be subject to legal proceedings in the ordinary course of our business that could result in significant harm to our business, financial condition and operating results.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.
  • Risks Related to our Reporting and Cybersecurity
  • We have not fully assessed our internal control over financial reporting. If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
  • Privacy breaches and other cybersecurity risks related to our business and vulnerabilities through the use of evolving tools such as Artificial Intelligence could negatively affect our reputation, credibility, and business.
  • Risks Related to our Capital Stock, Funding, and Trading in our Stock
  • We have incurred significant operating losses every quarter since our inception and anticipate that we will continue to incur significant operating losses in the future.
  • We may not be able to comply with all applicable listing requirements or standards of Nasdaq, and Nasdaq could delist our common stock.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our stock price is volatile, which could subject us to securities class action litigation, and your investment in our securities could decline in value.
  • An active market for our shares of common stock may not continue to develop.
  • If securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable research or other information about our business, our stock price and trading volume could decline.
  • Our corporate documents, Delaware law and certain warrants contain provisions that could discourage, delay or prevent a change in control of our company.

Legal proceedings

See Note 12, Contingencies and Note 14, Subsequent Events in the Notes to Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K — “Financial Statements and Supplementary Data,” for information regarding legal proceedings, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62